Podcasts

Recent Episodes

February 5, 2026

Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE

Deb Schrag, MD, MPH, medical oncologist, Memorial Sloan Kettering Cancer Center

February 4, 2026

Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

February 4, 2026

How Physics, Medicine, and Lived Experience Shaped a Career in Breast Cancer Research and Risk Evaluation: With Ross Camidge, MD; and Sofia Diana Merajver, MD, PhD

February 2, 2026

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center

January 31, 2026

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

Komal Jhaveri, MD, FACP, breast medical oncologist, Memorial Sloan Kettering Cancer Center

January 31, 2026

ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

January 31, 2026

Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

January 30, 2026

Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

January 30, 2026

Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD

January 30, 2026

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

All series

All Podcasts

Armeen Mahvash, MD, professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center; assistant professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

ByArmeen Mahvash, MD

October 27th 2025

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Vishal A. Patel, MD, FAAD, FACMS, associate professor, dermatology, GW School of Medicine & Health Sciences; director, Cutaneous Oncology Program, GW Cancer Center

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

ByVishal A. Patel, MD, FAAD, FACMS

October 23rd 2025

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

Eunice Wang, MD, professor, oncology, leader, Leukemia Clinical Disease Team, chief, leukemia, Department of Medicine, assistant member, Tumor Immunology Program, Department of Immunology, Roswell Park Comprehensive Cancer Center; associate professor, Department of Medicine, academic scholar, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

ByEunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, the University of Illinois

Metastatic Breast Cancer 2025 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

October 20th 2025

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

ByJ.Thaddeus Beck, MD, FACP

October 16th 2025

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

Girindra Raval, MD; Anand Jillella, MD, J. Harold Harrison, MD Distinguished University Chair in Medicine, professor, medicine & pediatrics, chief, Division of Hematology/Oncology, Augusta University Medical College of Georgia

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

ByGirindra Raval, MD,Anand Jillella, MD

October 15th 2025

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Dana M. Chase, MD; Premal H. Thaker, MD, MS; Zev Wainberg, MD; Sagus Sampath, MD

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

ByDana Chase, MD,Premal H. Thaker, MD, MS,Zev A. Wainberg, MD,Sagus Sampath, MD

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Joseph Jacob, MD, MCR, associate professor, urology, director, Urologic Oncology, Department of Urology, State University of New York Upstate Medical University

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

ByJoseph Jacob, MD, MCR

October 9th 2025

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Lyudmila Bazhenova, MD, clinical professor, medicine, the University of California San Diego (UCSD); medical oncologist, UCSD Moores Cancer Center

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

ByLyudmila A. Bazhenova, MD

October 8th 2025

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

Kanwal P. S. Raghav, MBBS, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine; associate vice president, Department of Ambulatory Medical Operations; executive medical director, Department of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

ByKanwal Raghav, MBBS, MD

October 6th 2025

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Anne Chiang, MD, PhD, associate professor, medicine, Section of Medical Oncology, associate cancer center director, Clinical Initiatives, Yale School of Medicine; Stephen Liu, MD, associate professor, medicine, Georgetown University, director, Thoracic Oncology, head, Developmental Therapeutics, the Georgetown Lombardi Comprehensive Cancer Center

FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD

ByAnne Chiang, MD,Stephen Liu, MD

October 2nd 2025

Drs Chiang and Liu discuss the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

ByStephen Liu, MD

October 1st 2025

Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.

Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD

ByAndrew Kuykendall, MD

September 29th 2025

Andrew Kuykendall, MD, provides an overview of the myelofibrosis treatment paradigm.

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

September 26th 2025

Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD

ByKohei Shitara, MD, National Cancer Center Hospital East

September 25th 2025

Kohei Shitara, MD, discusses optimizing treatment strategies and addressing unmet needs in resectable gastric and gastroesophageal junction cancers.

Asad Dean, MD, physician, Texas Oncology-Fort Worth Cancer Center

The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD

ByAsad Dean, MD

September 24th 2025

Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

September 23rd 2025

Establishing the Rationale for ADC and ICI Combinations in TNBC

September 22nd 2025

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

September 19th 2025

Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD

ByAlexander Drilon, MD

September 18th 2025

Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.

Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

ByDana Chase, MD

September 17th 2025

Dana M. Chase, MD, discusses the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies.

Evelyn Y. Wong, MD, consultant medical oncologist specializing in gastrointestinal cancers, National Cancer Centre Singapore

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

ByEvelyn Y.T. Wong, MD

September 15th 2025

Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore.

John N. Allan, MD, associate professor, clinical medicine, member, lymphoma faculty, Division of Hematology and Medical Oncology, member, CLL Research Center, Weill Cornell Medicine; Melissa Rubianes, hematology/oncology physician assistant, Weill Cornell

Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes

ByJohn Allan, MD, Weill Cornell Medicine

September 11th 2025

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD

BySamantha A. Armstrong, MD,Karine Tawagi, MD

September 8th 2025

Drs Armstrong and Tawagi discuss key aspects of soft tissue sarcoma management.

Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS

Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS

ByTara E. Seery, MD ,Paul E. Oberstein, MD,Priyadarshini Pathak, MBBS

September 4th 2025

Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.

Scott Kopetz, MD, PhD, FACP, deputy chair, Translational Research, professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, leader, Department of Cancer Center Support Grant, GI Program, TRACTION medical director, Division of Therapeutics Discovery, associate vice president, Translational Integration, The University of Texas MD Anderson Cancer Center

Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP

ByScott Kopetz, MD, PhD, FACP

September 3rd 2025

Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.

Tanya B. Dorff, MD, section chief, Genitourinary Disease Program, professor, Department of Medical Oncology & Therapeutics Research, City of Hope

Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

ByTanya B. Dorff, MD

September 2nd 2025

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

Patrick Y. Wen, MD, director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; professor, neurology, Harvard Medical School

FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD

ByPatrick Y. Wen, MD

September 1st 2025

Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.

Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD

ByMasatoshi Kudo, MD, PhD

August 21st 2025

Masatoshi Kudo, MD, discusses the evolving treatment landscape in HCC and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens.

Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD

By Neal S. Akhave, MD

August 14th 2025

Neal S. Akhave, MD, discusses the addition of toripalimab to the NCCN guidelines for nasopharyngeal carcinoma.

Podcasts

Recent Episodes

All series

Pediatrics

Career GPS

Marvels in Medicine

Talking Tumors

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

CME Podcasts

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

Metastatic Breast Cancer 2025 UPDATE

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD

Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD

The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD

Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes

Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD

Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS

Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP

Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD

Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD

Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma